Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885409 | 0.92 | KMT2A (0.76) | PKMALDH1A1MAPK1KMT2APOLB | |
| SCHEMBL3331192 | 0.89 | PKM (0.70) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL5438202 | 0.87 | SIGMAR1 (0.73) | PKMMAPK1KMT2ASIGMAR1 | |
| SCHEMBL20946428 | 0.86 | PKM (0.67) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL1410741 | 0.86 | SIGMAR1 (0.76) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL19563407 | 0.86 | SIGMAR1 (0.76) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL31356929 | 0.86 | ALDH1A1 (0.74) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL12302133 | 0.86 | ALDH1A1 (0.74) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL3719058 | 0.85 | PKM (0.69) | PKMALDH1A1MAPK1KMT2AEPHX2 | |
| SCHEMBL4769081 | 0.85 | SIGMAR1 (0.74) | PKMMAPK1KMT2ASIGMAR1NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946197-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060321-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-28 | — | — | US | disclosed |
| WO-2008040000-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1789055-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031929-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | PKM 556/4885ALDH1A1 1651/4885MAPK1 243/4885 |
| US-20080207621-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | PKM 2774/4885ALDH1A1 569/4885MAPK1 2649/4885 |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | PRKACA, PRKCE, MAP3K9 | PKM 473/4885ALDH1A1 2374/4885MAPK1 168/4885 |
| US-20130116216-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | PKM 1716/4885ALDH1A1 3161/4885MAPK1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.